Our Risk solution* is different, offering up to 2.4x more accuracy than traditional risk models like Tyrer-Cuzick and Gail,1,2 and is personalized based on age and image evidence directly from their mammogram. It’s near-term providing a risk probability score for developing breast cancer in the next 1 or 2 years giving women and care providers more actionable information to design personalized care plans.
Vendor
iCAD
Company Website
Expose cancer before it makes its move.
Advancements in breast cancer risk analysis are empowering radiologists to provide more personalized screening plans, allowing clinicians to catch cancer earlier. ProFound AI Risk is CE Marked and Health Canada Licensed, is not FDA Cleared, and is only available in the US for investigational use.
Know Her Risk. Protect Her Tomorrow. Personalized breast cancer risk estimation for one or two years ProFound AI® Risk is the first image-based, one or two year risk assessment tool – based on reading a 2D or 3D mammogram. As the field of mammography moves from age-based screening recommendations to more personalized risk-adaptive screening guidelines, iCAD is on the leading-edge of this exciting new realm that will enable clinicians to easily adapt to evolving screening practices and personalize patient care.
Good just isn’t good enough. ProFound AI Risk is 2.4x more accurate compared to traditional models.1
- **Traditional Mammograms: **With traditional mammograms, there’s a 25-40% reduction in mortality risk.
- However, the reduction is only when cancer is detected early, and 40% of cancers are still detected at a later stage. And 10-15% of all cancers are detected in the interval between scheduled mammograms, which are either entirely missed or masked during the previous mammogram.
- **Traditional Risk Assessments: **When radiologists apply traditional models and clinical guidelines to a patient who has a 20%+ lifetime risk of breast cancer score, they usually recommend an MRI for supplemental screening.
- However, tests often result in a high number of false positives due to low-to-moderate discrimination performance, such as specificity and sensitivity. Patients deserve a better solution.
Features
- Image-Based Risk Scoring: Uses mammogram data to predict short-term cancer risk with high precision.
- 2.4x More Accurate: Outperforms traditional models like Tyrer-Cuzick and Gail in predictive accuracy.
- Personalized Screening Plans: Supports tailored screening intervals and supplemental imaging decisions.
- Multi-Modality Support: Compatible with both 2D and 3D mammography systems.
- Regulatory Clearance: CE Marked and Health Canada Licensed; investigational use in the U.S.